Integra Lifesciences Holdings Corp (IART) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Integra Lifesciences reported revenue of $1.64B, up 1.5% from $1.61B the year before. Net income was -$516.5M (a -31.6% net margin), or -$6.74 per diluted share. Gross margin was 50.9% and operating margin was -30.2%. Operating activities generated $50.4M of cash, leaving -$31.1M of free cash flow. At fiscal year end, Integra Lifesciences held $3.60B in total assets against $2.56B in total liabilities, including $235.0M of cash and equivalents.
Open the full interactive Integra Lifesciences financials → Quarterly statements, key ratios, valuation history and price charts.
Integra Lifesciences Key Stats
| Share Price | $13.85 |
|---|---|
| Market Cap | $1.08B |
| Revenue YoY Growth | +1.5% |
| 52-Week Range | $8.90 – $19.85 |
| Shares Outstanding | 77.3 million (basic, 2026 Q2) |
Integra Lifesciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.54B | $1.56B | $1.54B | $1.61B | $1.64B |
| Cost of Goods Sold | $520.8M | $597.8M | $587.4M | $656.8M | $728.5M | $803.6M |
| Gross Profit | $851.0M | $944.6M | $970.3M | $884.7M | $882.1M | $831.6M |
| Operating Income | $151.4M | $197.2M | $238.9M | $111.5M | $28.4M | -$493.4M |
| Pre-Tax Income | $93.5M | $214.7M | $213.9M | $81.1M | -$18.2M | -$563.5M |
| Income Tax | -$40.4M | $45.6M | $33.3M | $13.3M | -$11.3M | -$47.0M |
| Net Income | $133.9M | $169.1M | $180.6M | $67.7M | -$6.9M | -$516.5M |
| Diluted EPS | $1.57 | $1.98 | $2.16 | $0.84 | -$0.09 | -$6.74 |
Integra Lifesciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $402.1M | $434.9M | $391.9M | $418.8M |
| Net Income | -$5.4M | -$1.7M | -$4.6M | $4.5M |
| Diluted EPS | -$0.07 | -$0.02 | -$0.06 | $0.06 |
Integra Lifesciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $470.2M | $513.4M | $456.7M | $276.4M | $246.4M | $235.0M |
| Current Assets | $1.24B | $1.15B | $1.16B | $1.06B | $1.08B | $1.16B |
| Total Assets | $3.62B | $3.78B | $3.89B | $3.78B | $4.04B | $3.60B |
| Current Liabilities | $401.0M | $340.0M | $320.9M | $307.0M | $922.1M | $456.0M |
| Total Long-Term Debt | $877.5M | $843.8M | $775.0M | $775.0M | $760.5M | $726.6M |
| Total Liabilities | $2.10B | $2.10B | $2.09B | $2.19B | $2.49B | $2.56B |
| Shareholders' Equity | $1.51B | $1.68B | $1.80B | $1.59B | $1.55B | $1.04B |
Integra Lifesciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $203.8M | $312.4M | $264.5M | $140.0M | $129.4M | $50.4M |
| Cash From Investing | -$68.1M | -$161.4M | -$58.6M | -$94.2M | -$390.8M | -$108.1M |
| Cash From Financing | $121.6M | -$98.2M | -$252.0M | -$229.9M | $237.9M | $28.3M |
| Free Cash Flow | $164.9M | $264.4M | $222.1M | $73.1M | $25.0M | -$31.1M |
Figures from Integra Lifesciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Integra Lifesciences financials page for every line item.
Integra Lifesciences Company Profile
| Ticker | IART |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Princeton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000917520 |
Frequently Asked Questions
What was Integra Lifesciences' revenue in fiscal 2025?
Integra Lifesciences (IART) reported revenue of $1.64B for fiscal 2025.
What is Integra Lifesciences' annual revenue history?
Integra Lifesciences' annual revenue by fiscal year: 2020: $1.37B; 2021: $1.54B; 2022: $1.56B; 2023: $1.54B; 2024: $1.61B; 2025: $1.64B.
What was Integra Lifesciences' net income in fiscal 2025?
Integra Lifesciences reported net income of -$516.5M for fiscal 2025.
What was Integra Lifesciences' earnings per share (EPS) in fiscal 2025?
Integra Lifesciences' diluted EPS was -$6.74 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Integra Lifesciences generate in fiscal 2025?
Integra Lifesciences generated -$31.1M of free cash flow in fiscal 2025.
What was Integra Lifesciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Integra Lifesciences reported revenue of $418.8M.
How much debt does Integra Lifesciences have?
Integra Lifesciences reported $726.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Integra Lifesciences are outstanding?
Integra Lifesciences reported a weighted average of 77.3 million basic shares outstanding in 2026 Q2.
What is Integra Lifesciences' market cap?
Based on its latest closing price, Integra Lifesciences (IART) has a market capitalization of about $1.08B.
When does Integra Lifesciences' fiscal year end?
Integra Lifesciences' fiscal year end, as registered with the SEC, is December 31.
Where is Integra Lifesciences headquartered?
Integra Lifesciences lists its business address in Princeton, New Jersey in its SEC filings.